How Analysts Feel About Flexion Therapeutics, Inc. (NASDAQ:FLXN)?

July 12, 2018 - By Harriett Tippett

Flexion Therapeutics, Inc. (NASDAQ:FLXN) LogoInvestors sentiment decreased to 0.95 in Q1 2018. Its down 2.12, from 3.07 in 2017Q4. It worsened, as 21 investors sold Flexion Therapeutics, Inc. shares while 36 reduced holdings. 25 funds opened positions while 29 raised stakes. 33.47 million shares or 50.24% less from 67.26 million shares in 2017Q4 were reported.
Citigroup stated it has 78,111 shares. Schroder Mgmt holds 512,477 shares or 0.02% of its portfolio. Berson & Corrado Inv Advsrs Ltd Com has invested 0.17% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Marathon Capital Management has 0.13% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Citadel Advisors Ltd Limited Liability Company holds 0% or 157,062 shares. Bnp Paribas Arbitrage owns 6,792 shares for 0% of their portfolio. Parametric Portfolio Ltd holds 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 18,560 shares. Cubist Systematic Strategies Limited Liability Com, Connecticut-based fund reported 17,022 shares. Royal Bancorp Of Canada owns 569,401 shares. Moreover, Monarch Prns Asset Management Ltd has 0.04% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Wellington Mngmt Gp Limited Liability Partnership reported 418,797 shares. Voya Mgmt Ltd Liability Corp, Georgia-based fund reported 14,198 shares. Millennium Limited Co accumulated 692,154 shares. 1.55 million are held by Vanguard Grp Incorporated. Ardsley Advisory reported 520,000 shares.

Since July 2, 2018, it had 0 insider buys, and 1 insider sale for $1.25 million activity.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Ratings Coverage

Among 4 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 4 analyst reports since February 1, 2018 according to SRatingsIntel. The stock has “Buy” rating by Wells Fargo on Tuesday, April 3. The firm has “Outperform” rating by BMO Capital Markets given on Friday, March 9. Below is a list of Flexion Therapeutics, Inc. (NASDAQ:FLXN) latest ratings and price target changes.

28/06/2018 Broker: Benchmark Rating: Buy New Target: $39 Initiates Coverage On
03/04/2018 Broker: Wells Fargo Rating: Buy New Target: $39.0000 Maintain
09/03/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $37 New Target: $36 Maintain
01/02/2018 Broker: Berenberg Rating: Buy New Target: $42 Initiates Coverage On

The stock increased 1.57% or $0.42 during the last trading session, reaching $27.22. About 323,678 shares traded. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has risen 39.11% since July 12, 2017 and is uptrending. It has outperformed by 26.54% the S&P500.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company has market cap of $1.02 billion. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. It currently has negative earnings.

More notable recent Flexion Therapeutics, Inc. (NASDAQ:FLXN) news were published by: Nasdaq.com which released: “Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row” on June 21, 2018, also Nasdaq.com with their article: “Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” published on July 03, 2018, Prnewswire.com published: “Alcami’s Extended Workbench Supports Commercial Supply of Flexion Therapeutics’s ZILRETTA® (triamcinolone …” on June 13, 2018. More interesting news about Flexion Therapeutics, Inc. (NASDAQ:FLXN) were released by: Investorplace.com and their article: “5 Biotech Stocks That Could Be the Next Amgen” published on June 27, 2018 as well as 247Wallst.com‘s news article titled: “Top Analyst Upgrades and Downgrades: CBS, Disney, Regions Financial, Salesforce, T-Mobile and Many More” with publication date: June 28, 2018.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: